Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
U.S. stock CFD derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
What Investors Didn't Like About Co-Diagnostics' Q4 Update
No one expected Co-Diagnostics (CODX +38.39%) to follow up its fantastic gain of nearly 940% in 2020 with anything close to that level this year. However, the molecular-diagnostics stock got off to a great start. The momentum is losing steam now, though.
Co-Diagnostics announced its fourth-quarter and full-year 2020 results after the market close on Thursday. The healthcare stock sank 8% in after-hours trading. Here are the highlights from the company's Q4 update.
Image source: Getty Images.
By the numbers
Co-Diagnostics reported revenue in the fourth quarter of $27.1 million, up 24% quarter over quarter. This result topped the average analyst revenue estimate of nearly $25 million.
The company announced Q4 net income of $12.8 million, or $0.43 per diluted share. This was lower than its Q3 earnings of $15.7 million, or $0.53 per diluted share. It also fell short of the consensus analyst estimate of earnings of $0.48 per share.
Co-Diagnostics ended the fourth quarter with cash, cash equivalents, and marketable securities totaling $47.3 million.
Behind the numbers
One product generated most of Co-Diagnostics' revenue growth in Q4: The Logix Smart COVID-19 Test. The company received Emergency Use Authorization (EUA) for the test in April 2020. It's been a fun ride for Co-Diagnostics, for the most part, since then.
The problem for the company in the fourth quarter wasn't due to revenue challenges. Co-Diagnostics' spending increased significantly more than its revenue did. In the third quarter, the molecular-diagnostics company's operating expenses totaled nearly $4 million. Co-Diagnostics' operating expenses in Q4 jumped 70% higher to $6.8 million.
However, the company's gross profit margin increased quite a bit. In the fourth quarter, its gross profit margin stood at 84%, up from 73% in the previous quarter.
Looking ahead
What will 2021 look like for Co-Diagnostics? CEO Dwight Egan tried to manage expectations saying that, "COVID-19 test sales may not be as robust as in 2020." However, the company thinks that demand will continue for its COVID-19 tests and other products over the long run.
The company hopes to win an additional EUA for its Logix Smart direct saliva test. It also could benefit if new coronavirus variants spread, boosting demand for COVID-19 testing.